Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)

A legfontosabb adatok

Ki végzi
The University of Queensland
Hol
Ausztrália, Belgium, Franciaország, Hongkong és Malajzia6 helyszín, 5 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
179 fő vett részt
Kezdés
2019. okt. 17.
Befejezés
2024. jan. 31.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A vizsgált kezelések
  • Blood sampling
  • Epithelial lining fluid sampling
  • Urine sampling
  • Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
A regiszteradat frissítve
2026. január 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult (≥18 years old) ICU patients
  • Confirmed or suspected either community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically diagnosed lung infection
  • Patient has been prescribed or is receiving one of the study drugs (benzylpenicillin, ceftriaxone, meropenem, or piperacillin/tazobactam) for the treatment of pneumonia in the ICU
  • Patient is sedated and receiving mechanical ventilation
  • Patient has arterial line and urinary catheter in situ for blood and urine samplings
  • Informed consent to participate in the study

Ki nem vehet részt

  • Receiving renal replacement therapy (RRT)
  • Has received study antibiotic for more than 72 hours (at time of Occasion 1) during current infective episode
  • Suspected or known hypersensitivity towards beta-lactam antibiotics (pre- or post-enrolment)
  • Pregnant patients or lactating mothers

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

5 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Pneumonia is the most common infection in intensive care unit (ICU) patients and occurs in 10% of all ICU admissions. Unfortunately, ICU patient outcomes remain poor with a high mortality rate associated with pneumonia despite recent therapeutic advances.

A teljes eredeti leírásKevesebb

Previous studies of antibiotics used in ICU patients, which includes ceftriaxone, meropenem and piperacillin/tazobactam, have quantified major differences in pharmacokinetics (PK) between ICU and non-ICU patients, with ICU patients displaying a unique spectrum of plasma concentration-time profiles. These PK differences can lead to suboptimal antibiotic concentrations in blood, which have been associated with a reduced likelihood of clinical cure for pneumonia. Furthermore, highlighting the importance of optimised dosing for pneumonia is that multi-drug resistant (MDR) pathogens emerge during antibiotic therapy in approximately half of the ICU patients, frequently emerging from the lung.

Previous work has highlighted how infection site concentrations determine patient outcome. For pneumonia, the infection site is best described as the epithelial lining fluid (ELF) in the lung.

Although optimal antibiotic therapy should be considered a priority for ICU patients with pneumonia to improve the persisting poor outcomes, the dosing regimens that can achieve therapeutic concentrations at the infection site (i.e., ELF) in ICU patients with pneumonia remain unknown.

The PNEUDOS study aims to address this significant knowledge gap by defining novel individualised dosing regimens that can maximise antibiotic efficacy by achieving therapeutic concentrations in the blood and ELF of ICU patients with pneumonia. These dosing regimens can then be validated in future clinical trials.

A vizsgálat 4 csoportja

  • Benzylpenicillin

    ICU patients receiving benzylpenicillin for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Kezelés: Blood sampling, Epithelial lining fluid sampling, Urine sampling és Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

  • Ceftriaxone

    ICU patients receiving ceftriaxone for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Kezelés: Blood sampling, Epithelial lining fluid sampling, Urine sampling és Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

  • Meropenem

    ICU patients receiving meropenem for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Kezelés: Blood sampling, Epithelial lining fluid sampling, Urine sampling és Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

  • Piperacillin/tazobactam

    ICU patients receiving piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Kezelés: Blood sampling, Epithelial lining fluid sampling, Urine sampling és Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multi-centre Study to Define Novel Individualised Dosing Regimens to Maximise Antibiotic Effectiveness for Treatment of Pneumonia in Intensive Care Units
A regiszteradat frissítve
2026. január 28.